Abingworth
Abingworth is a transatlantic life-sciences investment firm that provides capital and development expertise to biotechnology and biopharma companies. The firm invests across the company lifecycle — from seed and early-stage through clinical development and public-market positions — and operates offices in London, Menlo Park/San Francisco and Boston. Abingworth is part of Carlyle. As of 29 February 2024 the firm reported investments in 185 life-science companies, including multiple M&A transactions and IPOs.
Industries
Nr. of Employees
small (1-50)
Abingworth
1 St James's Market, London SW1Y 4AH, UK
Portfolio
Acquired by larger pharmaceutical companies (listed among exits).
#Biopharma / Immunology
Founding investor and seed funder; incubated in Abingworth's London office. Acquired by Takeda under a previously agreed option including development and regulatory milestones.
#Immuno-oncology / Cell therapy
Provider of clinical co-development services; involved in regulatory approvals cited (e.g., BOSULIF®).
#Clinical co-development / Late-stage development financing
Partner in co-development and manufacturing services; referenced in Abingworth materials.
#Clinical development services / Co-development
Acquired by larger pharmaceutical companies (listed among exits).
#Biopharma / Immunology
Founding investor and seed funder; incubated in Abingworth's London office. Acquired by Takeda under a previously agreed option including development and regulatory milestones.
#Immuno-oncology / Cell therapy
Provider of clinical co-development services; involved in regulatory approvals cited (e.g., BOSULIF®).
#Clinical co-development / Late-stage development financing
Partner in co-development and manufacturing services; referenced in Abingworth materials.
#Clinical development services / Co-development